Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II (IMPACT 2)

NCT05764356 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT05764356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05764356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II (IMPACT 2)
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
March 31, 2023
Completion date
December 31, 2027
Enrollment
2,000 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

apixaban, biomarker, bleeding, dabigatran, edoxaban, noacs, novel oral anticoagulants, pharmacodynamics, pharmacogenomics, rivaroxaban, rna profile, ticagrelor